Chemotherapy-induced Anemia
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Anemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy [Phase 2]
This is a Phase 2 clinical trial update for AND017 in chemotherapy-induced anemia, with the study currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Augmented Virtual Reality for Reducing Pain, Stress, Anxiety and Improve Self Efficacy in Adult Cancer Patients Undergoing Chemotherapy in The West Bank [NA]
This completed clinical trial evaluated augmented virtual reality as a nonpharmacologic approach to reduce pain, stress, and anxiety and to …
-
CLINICAL_TRIALS other · 2025-03-03Clinical Trial Update: Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies [Phase 2]
Notes a Phase 2 trial of SSS06 for chemotherapy-induced anemia in non-myeloid malignancies, sponsored by Shenyang Sunshine Pharmaceutical Co…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies [Phase 2]
This clinical trial update indicates a Phase 2 study of SAL-0951 for chemotherapy-induced anemia in patients with non-myeloid malignancies i…
-
CLINICAL_TRIALS research · 2024-11-26Clinical Trial Update: Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial from Fudan University is evaluating Vitamin C plus Cordyceps to address chemotherapy-related anemia in panc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012) [Phase 2]
A Phase 2 clinical trial evaluating sotatercept for chemotherapy-induced anemia in metastatic breast cancer was terminated; results posted i…
-
CLINICAL_TRIALS trial_result · 2023-06-06Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies [Phase 3]
A Phase 3 trial evaluating the efficacy and safety of Roxadustat for anemia in patients receiving chemotherapy for non-myeloid malignancies …
-
CLINICAL_TRIALS trial_result · 2023-01-30Clinical Trial Update: Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens [Phase 3]
Phase 3 trial assessing whether early erythropoietin reduces transfusion needs in pediatric patients with anemia, including neoplasms and ch…
-
CLINICAL_TRIALS trial_result · 2022-06-03Clinical Trial Update: Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Roxadustat for chemotherapy-induced anemia has completed with results posted.
-
FDA approval · 2018-05-15FDA Approved: RETACRIT — Original Application (Vifor (International) Inc.)
The FDA approved Retacrit (epoetin alfa-epbx) under Original Application BLA125545, establishing it as a biosimilar to epoetin alfa. The app…
-
FDA label_change · 2017-04-13FDA Approved: ARANESP — Supplemental Application (Amgen, Inc)
FDA approves Amgen's supplemental application for ARANESP (darbepoetin alfa), resulting in a label change for the product.
-
CLINICAL_TRIALS trial_result · 2017-03-20Clinical Trial Update: Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
The trial evaluating Retacrit (epoetin zeta), a biosimilar, for chemotherapy-induced symptomatic anemia in hematology and oncology has compl…
-
CLINICAL_TRIALS trial_result · 2016-12-20Clinical Trial Update: RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia [Phase 4]
The Phase 4 RAPID-2 trial evaluating alternate dosing of PROCRIT (epoetin alfa) to maintain hemoglobin in chemotherapy-induced anemia has be…
-
CLINICAL_TRIALS trial_result · 2016-11-01Clinical Trial Update: Erythropoietin and Iron Supplementation for Patients With Chemotherapy-induced Anaemia [Phase 4]
Phase 4 trial update evaluating erythropoietin with iron supplementation for managing chemotherapy-induced anemia.
-
CLINICAL_TRIALS trial_result · 2016-04-07Clinical Trial Update: Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia [Phase 4]
A Phase IV trial evaluating epoetin alfa (Hemax) for chemotherapy-induced anemia has completed.
-
CLINICAL_TRIALS trial_result · 2015-12-03Clinical Trial Update: A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA) [Phase 3]
Phase 3 trial comparing intravenous iron isomaltoside 1000 (Monofer) as monotherapy to oral iron sulfate for chemotherapy-induced anemia in …
-
CLINICAL_TRIALS trial_result · 2015-07-28Clinical Trial Update: Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology
This clinical trial update notes the completed study of the biosimilar epoetin alfa, Retacrit, for chemotherapy-induced anemia.
-
CLINICAL_TRIALS trial_result · 2013-06-27Clinical Trial Update: Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA) [Phase 1]
Phase 1 open-label pharmacokinetic study of iron isomaltoside 1000 (Monofer) given as a 500 mg IV bolus or 1000 mg IV infusion in patients w…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia [Phase 1]
Phase 1 pharmacokinetic study evaluating iron isomaltoside 1000 administered as a 250 mg IV bolus or a 500 mg intravenous infusion in patien…
-
FDA approval · 2013-03-27FDA Approved: PROCRIT — Supplemental Application (Janssen Products, LP)
FDA approved Janssen Products, LP's supplemental application for PROCRIT (erythropoietin), updating the product labeling under BLA103234.
-
CLINICAL_TRIALS trial_result · 2012-12-21Clinical Trial Update: Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy [Phase 2]
A Phase 2 trial of subcutaneously administered peginesatide in anemic cancer patients receiving chemotherapy has completed.
-
FDA approval · 2011-06-24FDA Approved: ARANESP — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for ARANESP (darbepoetin alfa) submitted by Amgen, Inc.
-
CLINICAL_TRIALS trial_result · 2011-05-23Clinical Trial Update: Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia [Phase 2]
This Phase 2 clinical trial update assesses alternate dosing regimens of epoetin alfa (PROCRIT) in cancer patients with chemotherapy-induced…
-
CLINICAL_TRIALS trial_result · 2011-05-19Clinical Trial Update: Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia [Phase 4]
This Phase 4 trial compares hematologic response between epoetin alfa (PROCRIT) and darbepoetin alfa (ARANESP) in chemotherapy-induced anemi…
-
CLINICAL_TRIALS trial_result · 2009-02-02Clinical Trial Update: A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy [Phase 3]
Phase 3 trial evaluating recombinant human erythropoietin in cancer patients with chemotherapy-induced anemia has completed.